Pneumothorax during lenvatinib treatment for hepatocellular carcinoma with lung metastasis

Lenvatinib is an inhibitor of tyrosine kinases, such as vascular endothelial growth factor receptor and fibroblast growth factor receptor, and was first approved for use in thyroid cancer in 2015 in Japan. Additional approval was given in March 2018 for its use as a first-line treatment for advanced...

Full description

Saved in:
Bibliographic Details
Published inClinical journal of gastroenterology Vol. 14; no. 1; pp. 288 - 292
Main Authors Kawanishi, Yasuhiro, Kuwahara, Michio, Utsunomiya, Masato, Ishida, Nobuko, Ishikawa, Yoichi, Hiroi, Makoto, Akimori, Toyokazu
Format Journal Article
LanguageEnglish
Published Singapore Springer Singapore 01.02.2021
Subjects
Abdominal Surgery
Case Report
Colorectal Surgery
Gastroenterology
Hepatology
Medicine
Medicine & Public Health
Surgical Oncology
Hepatocellular carcinoma
Pneumothorax
Lenvatinib
Lung metastasis
Online AccessGet full text

Cover

More Information
Summary:Lenvatinib is an inhibitor of tyrosine kinases, such as vascular endothelial growth factor receptor and fibroblast growth factor receptor, and was first approved for use in thyroid cancer in 2015 in Japan. Additional approval was given in March 2018 for its use as a first-line treatment for advanced or unresectable hepatocellular carcinoma. Herein, we report a case of pneumothorax during lenvatinib treatment for multiple lung metastases of hepatocellular carcinoma in a 71-year-old man. Although the development of pneumothorax during treatment with anticancer agents for lung metastases is well-known, this is the first report of pneumothorax induced by lenvatinib during treatment for lung metastases of hepatocellular carcinoma.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1865-7257
1865-7265
DOI:10.1007/s12328-020-01273-7